Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report

Anais Brasileiros de Dermatologia

Volumn 89, Issue 1, 2014, Pages 154-156

  Carvalho, Clarissa Luiza Dalla Bernardina ^a   Ortigosa, Luciena Cegatto Martins ^b  

^a UNIVERSIDADE DO OESTE PAULISTA UNOESTE   (Brazil)

^b NONE

Author keywords

Arthritis; Rheumatoid; Tumor necrosis factor alpha; Vitiligo

Indexed keywords

ALPHA TOCOPHEROL; CLOBETASOL; GLIBENCLAMIDE; INFLIXIMAB; INTERLEUKIN 1; METFORMIN; PHENYLALANINE; POLYPODIUM LEUCOTOMOS EXTRACT; PROPRANOLOL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; FEMALE; HUMAN; RHEUMATOID ARTHRITIS; VITILIGO;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO;

EID: 84896037167     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20142887     Document Type: Article

References (12)

1. Mota LMH, Laurindo IMM, Neto LLS. Artrite Reumatóide Inicial - Conceitos. Rev Assoc Med Bras. 2010;56:227-229.
2. Silva LC, Ortigosa LC, Benard G. Anti-TNF agents in the treatment of immuneme-diated inflammatory diseases: mechanisms of actions and pitfalls. Immunotherapy. 2010;2:817-833.
3. Ramírez-Hernández M, Marras C, Martínez-Escribano JA. Infliximab-Induced Vitiligo. Dermatology. 2005;210:79-80.
4. Lahita RG, Vernace MA. Vasculitis, Vitiligo, Thyroiditis, and Altered Hormone Levels After Anti-Tumor Necrosis Factor Therapy. J Rheumatol. 2011 Mar;38(3):579-580.
5. Hernández MV, Meineri M, Sanmartí R. Skin Lesions and Treatment With Tumor Necrosis Factor Alpha Antagonists. Reumatol Clin. 2013;9:53-61.
6. Duarte AA, Chehin FB. Moderate to severe psoriasis treated with infliximab - 53 patients: patients profile, efficacy and adverse effects. An Bras Dermatol. 2011;86:257-63.
7. Steiner D, Bedin V, Moraes MB, Villas RT, Steiner T. Vitiligo. An Bras Dermatol. 2004;79:335-351.
8. Correa MCT, Vargas LMG. Vitiligo. Rev Asoc Col Dermatol. 2009;17:76-86.
9. Bonnet N, Guis S, Koeppel MC, Roudier J, Grimaud JC, Jean-Pastor MJ, et al. Cutaneous events during anti-TNF alpha therapy: a prospective observational study of 41 cases. Ann Dermatol Venereol. 2010;137:12-20
10. Alghamdi KM, Khurrum H, Rikabi A. Worsening of vitiligo and onset of new pso-riasiform dermatitis following treatment with infliximab. J Cutan Med Surg. 2011;15:280-284.
11. Machado-Filho CDS, Almeida FA, Proto RS, Landman G. Vitiligo: analysis of grafting versus curettage alone, using melanocyte morphology and reverse transcrip-tase polymerase chain reaction for tyrosinase mRNA. Sao Paulo Med J. 2005;123:187-191.
12. Rao A, Gupta S, Dinda AK, Sharma A, Sharma VK, Kumar G, et al. Study of clinical, biochemical and immunological factors determining stability of disease in patients with generalized vitiligo undergoing melanocyte transplantation. Br J Dermatol. 2012;166:1230-1236.